Background: A systematic review and meta-analysis was designed to evaluate the effect of probiotics on diabetes and its associated risk factors. Methods: We systematically searched the Cochrane Library, PubMed, EMBASE and Web of Science to June 2016. We also hand-searched the citation lists of included studies and previously identified systematic reviews to identify further relevant trials. Our primary outcome variables included glucose, glycated hemoglobin (HbA 1c ) and insulin. The pooled standardized mean difference was used to compare the effect between the probiotics and controlled groups, and the pooled standardized mean difference effect size with a 95% confidence interval (CI) was estimated using a random-effect model. Heterogeneity was assessed with Cochran's Q and Higgins I 2 tests. Two reviewers assessed trial quality and extracted data independently. The analysis and bias for each included study was performed and assessed using Review Manager 5.2. Results: Eighteen randomized, placebo-controlled studies (n = 1056 participants, 527 consuming probiotics, 529 not consuming probiotics) were included for analysis. Comparing the probiotics groups with the control groups, there were statistically significant pooled standardized
Introduction
Probiotics were defined primitively by Fuller as live microbial feed supplements that beneficially affect the host, improving its intestinal microbial balance [1] . It has been demonstrated that probiotics could regulate gut microflora, which has health benefits for improving gut health and regulating plasma lipids [2, 3] . Furthermore, probiotics may have a role in preventing cardiovascular disease and other chronic diseases by increasing enzymatic antioxidant activity and decreasing lipid components, body weight and blood pressure [4, 5] .
Diabetes and obesity are now very epidemic, with increasing numbers of children and adults worldwide. Projections by the World Health Organization and the International Diabetes Foundation suggest that the incidence of diabetes or impairing glucose tolerance of adults will be up to 10% by 2030 [6, 7] . An abnormal metabolic profile, including impaired fasting glucose, insulin and HbA 1c , is a strong predictor of diabetes. Recently, it has been found that patients with diabetes showed an alteration in their gut microbial composition [8] , which indicated that probiotics may provide a new and promising way for regulating glucose and glycemic factors through modifying gut microflora [9] .
Several clinical trials have shown the effect of probiotics on the reduction of glucose, insulin, HbA 1c and other glycemic factors for type 2 diabetes mellitus (T2DM) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] and other diabetes or metabolic syndrome (defined as MS) [9, [20] [21] [22] [23] [24] [25] [26] . However, their dosages, bacterial strains and time of therapy were short of homogeneity. In addition, some of the studies have not shown a positive curative effect and their conclusions still remain controversial, for some studies gave negative results [12, 22] . Previous systematic reviews and meta-analyses have shown that probiotics had an effect on diabetes, but their pooled results showed a lack of accordance and their included studies were uncomprehensive, which could lead to a possibility of unreliable results and conclusions [27] [28] [29] .
Therefore, a systematic review of more studies at low risk of bias on the use of probiotic supplements was carried out to determine whether probiotics were effective in reducing the level of fasting glucose, insulin and HbA 1c . Meanwhile, lipid components including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were also evaluated as the second outcomes.
Materials and methods

Criteria for considering studies for this review Inclusion criteria
(1) The design of studies were randomized controlled trials (RCTs); (2) The studies included people with diabetes or associated risk factors, including overweight, obesity or MS; (3) Participants received randomized probiotic and placebo treatments; (4) Outcome variables, including glucose, HbA 1c , insulin, TC, TG, LDL-C or HDL-C, were reported; and (5) All trials involved human participants.
Both T2DM and other diabetes or MS were included for assessing and evaluating the effects of probiotics.
Exclusion criteria
(1) Trials on animals; (2) Non-placebo-controlled studies; (3) Studies about case reports; (4) Duplicated studies (the latest one with more entire outcome variables were included); and (5) The outcomes not meeting the inclusion criteria.
Types of outcome measures The primary outcomes
The reduction of glucose, HbA 1c and insulin in both T2DM and other MS patients.
Secondary outcomes
The reduction of TC, TG, LDL-C or HDL-C.
Search strategy
We searched the Cochrane Library, PubMed, EMBASE and Web of Science to June 2016. We also hand-searched the citation lists of included studies and previously identified systematic reviews to identify further relevant trials.
We searched the databases in English, including references of some literature we read.
Selection of studies
Two assessors independently screened the titles and abstracts of each study searched through the Cochrane Library, PubMed, EMBASE and Web of Science to June 2016. When relevant studies became certain, the full texts were obtained for further evaluation and quality assessment. The different opinions were resolved by discussion.
Data collection and quality assessment
Data for the analysis of the effect of probiotic intervention were extracted by a second reviewer. The extracted contents included country, study demographics, published years, trial design, duration of probiotic intake, dosage of probiotic use and probiotic regimen outcomes, using a standardized form. Outcome variables extracted included glucose, HbA 1c , insulin, TC, TG, LDL-C and HDL-C.
The quality assessment of human RCT studies was evaluated and scored using the previously validated 5-point Jadad scale [30, 31] . The questions used to assign Jadad scores included: (1) Was the study described as randomized? (2) Was the study described as double-blind? (3) Was there a description of withdrawals and drop outs? Scoring the item included: a. Either give a score of 1 point for each 'yes' or 0 points for each 'no'; b. Give an additional 1 point if each of the randomization and double-blinding were described appropriately; c. Deduct 1 point if the previously mentioned methods of randomization or blinding were inappropriate. Studies with scores of 3 or more were considered good quality.
Data collected were input into RevMan 5.2 software for analysis [32] .
Statistical analysis
The data of comparable outcome measures were pooled in a meta-analysis, using standard statistical procedures provided in RevMan 5.2 [32] , and the pooled standardized mean difference and effect size were used to analyze the mean differences and to compare the effect [33] . The effect measures pooled standardized mean difference with a 95% confidence interval (CI) was calculated to assess the effects of probiotics on the outcome variables. Subgroup analysis was used in this meta-analysis when the outcomes or intervening measures were significantly different.
The heterogeneity between studies was evaluated with I 2 . I ≥ 50% was deemed to represent significant heterogeneity [34, 35] , and a pooled standardized mean difference was estimated using a random effect model. On the contrary, if statistical study heterogeneity was not observed (I 2 ≤ 50%), a fixed effects model was used. A p-value ≤0.10 was considered statistically significant for heterogeneity, while I 2 = 0% indicates no observed heterogeneity. Publication bias was assessed by Begg's and Egger's tests. If the shape of the funnel plots revealed no obvious evidence of asymmetry, we considered that there was no obvious publication bias. Finally, sensitivity analysis was conducted to assess whether the inferences overly depended on a particular study.
Studies analyzed in the meta-analysis were only those that compared placebo or no treatment with probiotics (placebo-controlled studies).
Results
Included studies
Eighteen randomized, placebo-controlled studies (n = 1056 participants, 527 consuming probiotics, 529 not consuming probiotics) were included for analysis. Of the 18 RCTs, 10 studies, including 538 people (268 consuming probiotics, 270 not consuming probiotics) were about T2DM, and eight studies included 518 people (259 consuming probiotics, 259 not consuming probiotics) were about other MS, including overweight and gestational diabetes mellitus (generally defined as MS).
The search process and strategy (see Figure 1 ) of all the 18 included studies are displayed in a flow diagram [36] . Further characters of the eligible studies are presented in Table 1 . One study was excluded in that it was not about the outcomes of the inclusion criteria [37] . One ineligible study did not provide the change of the outcome variables [38] .
Quality assessment
According to the 5-point Jadad scale, in the end, three studies had scores of 3, nine studies had scores of 4 and six studies had scores of 5 ( Table 1 ).
Effects of probiotics
Effects of probiotics on glucose
All of the 18 studies were included for assessing the effects of probiotics on glucose. As Figure 2 shows, Comparing the probiotics groups with the control groups, the significant pooled standardized mean difference on the reduction of glucose was −0.61 (95% CI −0.98, −0.24; p = 0.001), with the estimation by a random effect model, as the significant heterogeneity between studies (I 2 ≥ 50%, p ≤ 0.05). For subgroup analysis, the pooled standardized mean difference revealed more significant reduction of glucose in the T2DM group, as the pooled standardized mean difference was −0.43 (95% CI −0.75, −0.11; p = 0.008), than in the MS group (−0.43, 95% CI −0.89, −0.13; p = 0.02).
Effects of probiotics on insulin
Eleven studies, with 754 participants (369 consuming probiotics, 385 not consuming probiotics), reported the effects of probiotics on fasting insulin. Probiotics had a statistically significant effect on fasting insulin levels in terms of a reduction in the probiotics group, with a pooled standardized mean difference of −0.49 (95% CI −0.93, −0.04; p = 0.03) and significant heterogeneity (I 2 = 88%, p < 0.0001). To assess the source of heterogeneity, subgroup analysis identified that probiotics had a significant effect on the reduction of insulin in T2DM patients, with a pooled standardized mean difference of −0.36 (95% CI −0.60, −0.12; p = 0.003) and no heterogeneity (I 2 = 0%, p = 0.96). However, there was no significant reduction in the trials among participants with other MS patients or other health conditions (generally defined as MS) with a pooled mean difference of −0.63 (95% CI −1.36, −0.10; p = 0.09), which was inconsistent with the result from the review of Sun [28] (Figure 3 A meta-analysis comparing probiotics to control groups showed obvious significance on the reduction of HbA 1c , as the pooled standardized mean difference was −0. reported LDL-C and HDL-C values. According to the meta-analysis, there were no significant reductions in either LDL-C or HDL-C, for the pooled standardized mean differences of LDL-C and HDL-C were −0.28 (95% CI −0.66, 0.10; p = 0.15) and 0.12 (95% CI −0.55, 0.78; p = 0.73), respectively.
For subgroup analysis, probiotics had no statistically significant effect on the reduction of LDL-C (−0.25, 95% CI −0.92, 0.41; p = 0.45) in the T2DM group, but was significant in the MS group (−0.29, 95% CI −0.54, −0.04; p = 0.02) ( Table 2 and Supplementary Figure 3 ). For HDL-C, there were no significant reduction in either the T2DM group, with a pooled standardized mean difference of −0.08 (95% CI −1.21, 1.04; p = 0.88), or the MS group, with a pooled standardized mean difference of 0.18 (95% CI −0.36, 0.72; p = 0.51) ( Table 2 and Supplementary  Figure 4) . 6 . Subgroup, sensitivity analysis and publication bias Subgroup analysis was conducted to find the effects of probiotic diet on glucose. We divided the included studies into three subgroups according to the 5-point Jadad scale, with scores of 3, 4 and 5. The pooled effect revealed no significance in subgroups of scales 3 and 5, for the pooled standardized mean differences were −0.25 (95% CI −0.72, 0.22; p = 0.30) and −0.93 (95% CI −1.87, 0.01; p = 0.05), respectively. However, there was a statistically significant effect in subgroup of scale 4, with the pooled standardized mean difference of −0.60 (95% CI −1.13, −0.08; p = 0.02). In addition, for the subgroup analysis of the duration of intervention, no significance was found in the subgroup of duration <8 weeks, for the pooled standardized mean difference was −0.45 (95% CI −0.94, 0.05; p = 0.08), but a significant effect was found in the subgroup of duration >8 weeks as the pooled standardized mean difference was −0.75 (95% CI −1.27, −0.24; p = 0.004) ( Table 3 ).
Sensitivity analyses revealed that two particular studies, by Dolatkhah et al. [21] and Rajkumar et al. [9] , significantly affected the pooled effects for glucose in the subgroup of MS, in that the pooled standardized mean difference changed from −0.89 (95% CI −1.65, −0.13; p = 0.02) to −0.44 (95% CI −1.01, 0.13; p = 0.13) when the study by Dolatkhah et al. was excluded and to −0.49 (95% CI −1.15, 0.17; p = 0.14) when the study by Rajkumar et al. was excluded. For TC and TG, when the study by Asemi et al. [14] was excluded, the pooled standardized mean differences in the T2DM group changed from −0. [16] significantly affected the pooled effects in the subgroup of T2DM, in that the pooled standardized mean difference changed from −0.08 (95% CI −1.21, 1.04; p = 0.88) to 0.82 (95% 0.02, 1.62; p = 0.04) when the study was excluded. The results were stable for the other analysis.
Funnel plots were conducted for assessing the publication bias of included literature and we could roughly assess the publication bias by seeing whether their shapes showed any obvious asymmetry. The funnel plots showed no clear evidence of publication bias with regard to the effects on glucose, HbA 1c , insulin, TC, TG, LDL-C and HDL-C ( Figures 5A-C and 6A-D) .
Discussion
Many studies have assessed the effect of probiotics on metabolic profiles in people [39] , and several systematic reviews and meta-analyses have shown that probiotics had an effect on diabetes, but their pooled results showed a lack of accordance and their included studies were uncomprehensive, which could lead to a possibility of unreliable results and conclusions [27] [28] [29] . Thus, we performed this meta-analysis demonstrate the effects of probiotics for T2DM and other MS patients in reducing the level of fasting glucose, insulin and HbA 1c .
Our results statistically supported the conclusions that probiotic consumption resulted in an overall reduction in glucose and HbA 1c , which were consist with the conclusions in a previous review [28] . However, the effect on insulin showed a lack of accordance with the review by Sun, for our results revealed that probiotics also had a significant effect on insulin, but only for T2DM patients and not for other MS patients. In addition, the effect on HbA 1c was also only for T2DM patients. Besides, though the effects were significant in both the T2DM and other MS groups, the effect was more significant in the T2DM group. Similar results also were observed in animal studies [40] [41] [42] . Moreover, our sensitivity analysis found statistical significance in the lipid profile in spite of the overall non-significance in lipid components when one or more particular studies were excluded. None of the studies included in this meta-analysis reported any adverse side-effects related to the use of probiotics, indicating that it was safe to use probiotics. This finding could guide the treatment of diabetes or other MS patients. Some probiotic production or food could be added to their diet plan to improve glucose levels. Comparing the probiotics groups with the control groups, the pooled result showed significant reduction of glucose. For subgroup analysis, the pooled result revealed more significant reduction of glucose in the T2DM group than in the MS group. Std., Standardized mean difference.
Probiotics may become one of the adjuvant therapies in the future for diabetes patients.
The true mechanism or association between probiotics and glucose or glycemic factors have not been clarified. There are several possible explanations for the effects of probiotics on glucose or glycemic factors. One of the possible mechanisms by which this effect occurs is through the impact of probiotics on changing intestinal microbiota [8, 43] . Probiotic consumption can balance intestinal microbiota for people with T2DM, which might have been caused by the short-chain fatty acids (SCFA) produced from probiotic consumption [44] . Probiotics were effective in suppressing the progression of streptozotocin-induced diabetes [42] , in that streptozotocin has the ability to selectively kill pancreatic β-cells, which can decrease endogenous insulin release and increase glucose intolerance [45] . This indicates that probiotic consumption may have an anti-diabetic effect through the role in protecting pancreatic β-cells from damage [42] . In addition, current research has suggested that oxidative damage and antioxidative ability play an important role in the pathogenesis of diabetes [46] . The antioxidant activity of probiotics has been confirmed in a previous experiment [47] . Probiotics have been reported to exert anti-diabetic effects against insulin resistance by increasing liver natural killer T (NKT) cells. Probiotic treatment also improves insulin resistance and inflammation by modulating tumor necrosis factor alpha (TNFα) expression and reducing nuclear factor Table 3 : Subgroup analyses of the effects of probiotics on glucose by the quality of the Jadad scale and duration of intervention (standardized mean differences and 95% CI).
Subgroups
Number kappa-light-chain-enhancer of activated B cell (NF-kB) binding activity [48] . Nevertheless, there were several limitations in this meta-analysis. The main limitations were the multiple species of probiotics and the dosage of probiotics. The number of strains used in the studies were related to the effects of probiotics on the glucose and glycemic factors. Besides, the duration of probiotic consumption may pose another significant limitation. For example, no significance was found for glucose in the subgroup of duration <8 weeks, for the pooled standardized mean difference was −0.45 (95% CI −0.94, 0.05; p = 0.08), but the significant effect was found in the subgroup of duration >8 weeks as the pooled standardized mean difference was −0.75 (95% CI −1.27, −0.24; p = 0.004). The other limitations may be the probiotics in capsule or in milk form, the number of participants, the complications of patients and the quality of the studies.
Further work: our search strategy for this review was comprehensive, broad and systematic, with hand-searching some references of included studies and previous systematic reviews. Taking the aforementioned limitations into account, further research needs to clarify the effect of different species of probiotics and the dosage of probiotics in patients. Future research using RCTs with a large sample size is also needed to confirm that such alternative nutrition regimens are effective with regard to the reduction of glycemic factors. In addition, studies with different durations of intervention are needed to clarify whether there is a time-effect or dose-effect. With further studies being completed and available, more clinically convincing results may be drawn later.
Conclusions
Despite many differences and influencing factors, we could cautiously draw a conclusion that probiotics may be beneficial to diabetes, with consideration of the evident statistical significance. Probiotics may have beneficial effects on the reduction of glucose, insulin and HbA 1c for diabetes, especially for patients with T2DM. However, we did not find a significant reduction of insulin and HbA 1c in patients with MS. In addition, probiotics may have no effect on the lipid profile. 
